Edgar Filing: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. - Form 8-K

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Form 8-K September 26, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 26, 2017

THERAPEUTIC SOLUTONS INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada 000-54554 45-1226465

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification Number)

4093 Oceanside Boulevard, Suite B Oceanside, California 92056

(Address of Principal Executive Offices and Zip Code)

(760) 295-7208

(Issuer's telephone number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Edgar Filing: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of

the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. - Form 8-K

Item 8.01 Other Events.

On August 18, 2017, by unanimous written consent, the Board of Directors of Therapeutic Solutions International, Inc., deemed it to be in the best interest of the Company to cancel the reverse stock-split of its common stock of one (1) new common share for each two (2) old common shares of stock, formerly approved by the Board of Directors on August 22, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 26, 2017

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

By: /s/ Timothy Dixon

Timothy Dixon

Chief Executive Officer